Thanks Tony, I must say that the timing of my post was...

Thanks Tony,
I must say that the timing of my post was opportune. It is interesting to reread the post through the lens of the Directors Report and in particular the following disclosure;

"Phylogica is maintaining discussions with Janssen in the expectation that its emerging oncology research will reengage the collaboration."

I think that we can modify the title of the thread to Timeline to a Redecision. Three months is a long time in biotech land.

What does it tell us about the recent work by Phylogica in terms of demonstrating that "it can successfully deliver therapeutic classes of drugs inside cells for new commercial partners"?

Does it suggest that Phylogica has failed to demonstrate anything of value within its emerging oncology research; does it suggest that Phylogica has made some advancement but nothing to write home about or does it suggest that the recent research has dramatically advanced the science forward in terms of the delivery of therapeutic classes of drugs at 25-50 times greater potency.

The news-straitjacket imposed by the collaboration has been removed. Hopefully we can expect greater disclosure going forward in relation to progress within the emerging field of the intracellular delivery of drugs.